Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

AMG 386 and Abiraterone for Advanced Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms
Neoplasm, Prostate
Prostate Cancer
Neoplasm,Prostatic

Interventions: Drug: AMG 386
Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2012-03-14

Last Posted Date: 2019-03-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT01553188

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Phase 2

Withdrawn

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma
Stage I Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2012-02-27

Last Posted Date: 2016-03-03

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT01539174

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Steroid Treatment for Hypereosinophilic Syndrome

Phase 4

Completed

Conditions: Leukocyte Disorder
Eosinophilia
Hypereosinophilic Syndrome
Hematologic Diseases

Interventions: Drug: prednisone

First Posted Date: 2012-02-02

Last Posted Date: 2022-02-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 26

Registration Number: NCT01524536

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2012-02-01

Last Posted Date: 2024-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT01523977

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
UCSF, San Francisco, California, United States

and more 5 locations

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Phase 3

Terminated

Conditions: Prostatic Neoplasms
Castration Resistant Prostate Cancer
Pain
Prostate Cancer

Interventions: Drug: mitoxantrone
Drug: cabozantinib
Drug: prednisone

First Posted Date: 2012-01-31

Last Posted Date: 2018-05-23

Lead Sponsor: Exelixis

Target Recruit Count: 119

Registration Number: NCT01522443

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Phase 3

Completed

Conditions: Metastatic Breast Cancer
Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Abiraterone acetate
Drug: Prednisone

First Posted Date: 2012-01-25

Last Posted Date: 2022-05-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 32

Registration Number: NCT01517802

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Stage IV Prostate Adenocarcinoma
Hormone-Resistant Prostate Cancer
Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma

Interventions: Drug: Abiraterone Acetate
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Prednisone

First Posted Date: 2012-01-02

Last Posted Date: 2021-05-14

Lead Sponsor: University of Washington

Target Recruit Count: 32

Registration Number: NCT01503229

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone
Drug: Placebo
Drug: Apitolisib
Drug: Ipatasertib
Drug: Prednisone
Drug: Prednisolone

First Posted Date: 2011-12-06

Last Posted Date: 2023-09-14

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 298

Registration Number: NCT01485861

Locations: 🇺🇸
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
🇺🇸
Kaiser Permanente Medical Ctr, Honolulu, Hawaii, United States
🇨🇿
Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia

and more 56 locations

Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

First Posted Date: 2011-11-23

Last Posted Date: 2013-03-06

Lead Sponsor: New Mexico Cancer Care Alliance

Registration Number: NCT01478308

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Phase 2

Terminated

Conditions: Recurrent Prostate Cancer
Stage I Prostate Cancer
Diarrhea
Stage IIB Prostate Cancer
Hormone-resistant Prostate Cancer
Stage IIA Prostate Cancer
Stage III Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: cabazitaxel
Drug: prednisone
Drug: octreotide pamoate
Other: questionnaire administration
Drug: octreotide acetate

First Posted Date: 2011-11-10

Last Posted Date: 2014-11-24

Lead Sponsor: University of Southern California

Target Recruit Count: 9

Registration Number: NCT01469338

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy